Concepedia

Author

Jacopo Giuliani

University of VeronaORCID

Also Known As

J Giuliani, J. Giuliani, JACOPO GIULIANI, Jacopo Giuliani, Riccardo Guelfi, jacopo giuliani

169

Publications

721

Citations

14

H-Index

26

Concepts

All Affiliations

University of VeronaUniversity of FerraraATS Sardegna (Italy)State Innovation Exchange
JG

About

Jacopo Giuliani is an author at University of Verona specializing in medicine, oncology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

98

2

Health Sciences

1

1

31

3

Gastroenterology

1

1

13

4

Health Law

1

1

31

5

Health Policy

1

1

31

Jacopo Giuliani

×

12

Publications

246

Citations

11

H-Index

YearCitations

The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab

Jacopo Giuliani, Andrea Bonetti

Anticancer Research

2019

42

Implications of drugs with rebate in Europe

Andrea Bonetti, Jacopo Giuliani

The Lancet Regional Health - Europe

2021

31

Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer

Francesco Fiorica, Umberto Tebano, Milena Gabbani,

Cancers

2021

28

Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer.

Andrea Bonetti, Jacopo Giuliani, Franco M. Muggia

PubMed

2014

24

Psychological impact of Covid-19 pandemic on oncological patients: A survey in Northern Italy

Eva Pigozzi, Daniela Tregnago, Lúcia Costa,

PLoS ONE

2021

24

Trends in Survival for Patients with Metastatic Breast Cancer: Is Survival Improving?

Jacopo Giuliani, Andrea Bonetti

Tumori Journal

2015

16

Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma

Jacopo Giuliani, Andrea Bonetti

Clinical Genitourinary Cancer

2018

16

Centrosome Linker–induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers

Andrea Remo, Erminia Manfrin, Pietro Parcesepe,

Molecular Cancer Research

2018

14

Immunotherapy in first-line for advanced non-small cell lung cancer: <br>a cost-effective choice?

Jacopo Giuliani, Andrea Bonetti

Recenti Progressi in Medicina

2019

14

The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer

Jacopo Giuliani, Andrea Bonetti

Journal of Oncology Pharmacy Practice

2020

14

Page 1